Rosiglitazone and cardiovascular risk.
Psaty
Bruce M
BM
Furberg
Curt D
CD
D016907:Adverse Drug Reaction Reporting Systems; D002318:Cardiovascular Diseases / Q000401:mortality*; D017327:Clinical Trials, Phase IV as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone